SEC Form 4/A · accession 0000899243-16-028321
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
John G. Aunins
Officer — Chief Technology Officer & EVP
Period of report
Apr 25, 2016
Accepted (ET)
Aug 31, 2016 · 8:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3 | Apr 25, 2016 | S | 18,640 | $31.94 | D | 56,060 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This line item is not new or revised, but is being reported again solely to gain access to the electronic filing system for filing this amendment. This Form 4 when it was initially filed by the Reporting Person on April 27, 2016 and four Forms 4 filed by the Reporting Person after that date incorrectly stated the date the Reporting Person adopted his 10b5-1 trading plan. This amendment is being filed to correct such date.
- F2The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2016.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $31.48 to $32.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.